Core Lithium finalises second Glencore fines sale
Core Lithium (ASX:CXO) finalises a binding agreement with Glencore to sell 25,000 tonnes of lithium fines from its Finniss operation stockpile.

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Core Lithium (ASX:CXO) finalises a binding agreement with Glencore to sell 25,000 tonnes of lithium fines from its Finniss operation stockpile.
A key architect of the European Union’s Markets in Crypto-Assets Regulation (MiCA) has argued that policymakers should focus on tokenisation and real-world asset frameworks rather than introducing new rules for decentralised finance.
ASIC confirmed an enforcement approach for the upcoming ban on advertising superannuation funds during employee onboarding.
Vivakor (NASDAQ:VIVK) reported a narrower net loss and significantly stronger gross margins for the first quarter of 2026, signaling early progress in the company’s ongoing pivot toward its higher-margin midstream and logistics operations.
OFS Credit Company (NASDAQ:OCCI) reported a contraction in its net asset value and a decline in quarterly investment income for its fiscal second quarter, driven by yield compression and weaker cash flow dynamics across its structured credit holdings.
CECO Environmental (NASDAQ:CECO) raised its full-year 2026 financial guidance, factoring in the initial operational contributions from its recently finalized acquisition of Thermon Group Holdings.
Parsons (NYSE:PSN) has secured an additional $73 million contract from the Air Force Research Laboratory to continue supporting its Global Application Research, Development, Engineering and Maintenance (GARDEM) mission.
Powerlaw (NASDAQ:PWRL) reported a sequential increase in its monthly net asset value, driven by positive valuation updates across its investment portfolio as of the end of May.
PureTech Health reported that its founded entity, Seaport Therapeutics (NASDAQ:SPTX), achieved positive clinical results from the multiple-ascending dose portion of its Phase 1 proof-of-concept trial evaluating its lead anti-anxiety candidate, GlyphAgo.
Researchers from the Initiative for Cryptocurrencies and Contracts have warned that autonomous artificial intelligence agents with access to cryptocurrency wallets could become effectively unstoppable if deployed maliciously or allowed to escape their intended operating environments.